CompletedNCT04324359Updated Jan 15, 2025Results posted

Study to See How Well an Eye Drop, SURF-201, Works and What Side Effects There Are in Cataract Surgery Subjects

A Phase 2 interventional study of SURF-201 and Placebo in Post-surgical Ocular Inflammation and Post-surgical Ocular Pain, sponsored by Surface Ophthalmics, Inc.. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-15.

Sponsored by Surface Ophthalmics, Inc. · Phase 2, Interventional, and Treatment

Phase: Phase 2
Study type: Interventional
Enrollment: 91
Allocation: Randomized
Ages: 18 Years and older
Sex: All

Study summary

SURF-201 is being studied for the treatment of eye inflammation and pain in people who are undergoing cataract surgery. SURF-201 is an investigational drug (which means the study drug is currently being tested) in the form of a sterile eye drop.

The purpose of this research study is to see how well SURF-201 works and what side effects there are, and to compare it with Vehicle (placebo). This study will involve about 80 study participants at several different research sites in the United States.

Conditions studied

Post-surgical Ocular Inflammation
Post-surgical Ocular Pain

Browse trials for

In context

Cataract

1,701 studies on the registry are indexed under Cataract; 230 are open to participants now.

This study's enrollment of 91 is above the median of 80 across 1,155 interventional studies indexed under Cataract.

Browse Cataract studies →

Lead sponsor

Surface Ophthalmics, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: No

Inclusion criteria

Adult subjects age 18 years or older scheduled for uncomplicated unilateral cataract surgery with posterior chamber intraocular lens (IOL) implantation.
Subjects must be able to understand and sign the Informed Consent Form (ICF).
Female subjects of childbearing potential must agree to and submit a negative urine pregnancy test before any study-specific procedures are performed. The subjects must be using and continue to use a suitable method of contraception for the duration of the study: spermicide with barrier, oral contraceptive, transdermal contraceptive, injectable or implantable contraceptive, intrauterine device (IUD), abstinence or surgical sterilization of a partner. If a subject is not of childbearing potential (e.g., has been postmenopausal for at least 12 months or is premenarchal, or has undergone a hysterectomy, bilateral oophorectomy or a bilateral tubal ligation), a urine pregnancy test and use of a suitable method of contraception for the duration of the study will not be required.
Subjects must have a best-corrected visual acuity (BCVA) of at least +1.0 log of the minimum angle of resolution (logMAR) (Snellen equivalent of 20/200) in the non-study eye (fellow eye).
Subjects must have an intraocular pressure (IOP) of >8 mmHg and ≤22 mmHg in the study eye (surgery eye).
Subject must agree to maintain their current dosing regimen throughout the study period (from Screening through Day 32) if they are currently using topical cyclosporin-A or Xiidra (lifitegrast 5%).
Subjects must be willing and able to attend all study visits and follow all instructions.
Subjects must be able to self-instill the study drug (if unable, a caregiver must be available to instill all doses of the study drug).
Subjects must agree to avoid any medications which are disallowed (as defined by the protocol).

Exclusion criteria

Exclusion Criteria:

Subject has any intraocular inflammation (cells and flare in the anterior chamber) or ocular pain (pain score of >0) in either eye prior to surgery.
Subject has any extraocular inflammation in the study eye prior to surgery (blepharitis is allowed if only scurf is present without any concurrent conjunctivitis or lid erythema/edema) or ongoing uveitis.
Subject has a history of diabetic retinopathy and/or previous vitrectomy in the study eye within the last 2 years prior to Screening which, in the investigator's opinion, is clinically significant and could impact the normal outcome of an uncomplicated cataract surgery.
Subject has a diagnosis of severe dry eye in the study eye.
Subject has any sign of iritis or scleritis in the study eye.
Subject has a history of glaucoma surgery in the study eye within the last 2 years prior to Screening.
Subject has a history of retinal surgery in the study eye within the last 2 years or plans to undergo retinal surgery in the study eye during the study period (from Screening through Day 32)
Subject has a history of Fuchs' dystrophy in the study eye.
Subject has guttata or chalazion in the study eye.
Subject has undergone radial keratotomy, photorefractive keratotomy, advanced surface ablation, corneal transplant, or LASIK in the study eye within the last 2 years prior to Screening.
Subject plans to undergo cataract surgery in the non-study (fellow) eye during the study period (from Screening through Day 32).
Subject plans to undergo additional ocular surgery (including femtosecond laser-assisted cataract surgery, minimally invasive glaucoma surgery, astigmatic keratotomy, limbal relaxing incision surgery, mechanical pupillary expanders, conjunctival incisions, and vitrectomy) in either eye during the study period (from Screening through Day 32).
Subject has a history of intraocular injections in the study eye within 6 months prior to Screening.
Subject has a history of herpes simplex infection in either eye.
Subject has active corneal, conjunctival or canalicular pathology (including ocular infection [bacterial, viral or fungal]) in the study eye. Specifically, active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of the ocular structures (such as fungal keratitis).
Subject has thinning of the cornea or sclera.
Subject plans to undergo uncomplicated unilateral cataract surgery with the aid of anterior capsular staining products (e.g., Trypan blue) or with the aid of a femto (femtosecond) laser.
Subject has undergone anti-neoplastic therapy within the last 2 years prior to Screening or plans to undergo anti-neoplastic therapy during the study period.
Subject has a history of use of medications to treat benign prostatic hyperplasia that, in the opinion of the investigator, limits adequate dilation of the pupil to safely perform uncomplicated cataract removal and IOL implantation.
Subject has a history of liver disease within the last 5 years prior to Screening.
Subject has a history of previous ocular trauma in the study eye that places the study eye at risk of increased post-surgical complications or inflammation.
Subject has or had a known blood dyscrasia or bone marrow suppression.
Subject has an active or chronic/recurrent ocular or systemic disease that is not controlled and may have an impact on would healing (e.g., diabetes mellitus, systemic connective tissue disease, severe atopic disease).
Subject is suffering from alcohol and/or drug abuse.
Subject has a known hypersensitivity or poor tolerance to corticosteroids or any component of the study drug or any of the procedural medications such as anesthetic and/or fluorescein drops, dilating drops, etc.
Female subjects who are currently pregnant or nursing or are planning to become pregnant during the study or have a positive pregnancy test.
Subject has previously participated in this study protocol.
Subject used (within 30 days of initiation of study treatment) or is anticipating concurrent use of an investigational drug or device.
Subject has a condition or a situation which, in the investigator's opinion, might put the subject at increased risk, confound the study data or interfere significantly with the subject's study participation.
Subject would be wearing contact lens in either eye during the dosing period of Day -1 to Day 14.
Subject is taking a medication that the investigator feels might interfere with the study parameters.
Subject tests positive for the Coronavirus Disease 2019 (COVID-19) virus prior to Visit 1 (Day -14 to Day -2).

Study design

Phase: Phase 2
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment: 91 participants (actual)

Study arms

Experimental
SURF-201
0.2% topical preservative-free corticosteroid solution (0.2% betamethasone sodium phosphate)
Drug: SURF-201
Placebo comparator
Vehicle
Topical preservative-free vehicle (Placebo)
Drug: Placebo

Interventions

DrugSURF-201
One drop twice daily (BID) in the study eye for 16 days.
Also known as: 0.2% topical corticosteroid solution
DrugPlacebo
One drop twice daily (BID) in the study eye for 16 days.
Also known as: Vehicle

What researchers measure

Primary outcomes

Anterior Chamber Cell (ACC) Grade: Number of Participants Achieving an ACC Grade of 0
The Investigator used a slit lamp biomicroscope to assess ACCs in the study (surgery) eye. ACC counts were graded as follows: ACC Grade 0 = 0 cells were seen ACC Grade higher than 0 = 1 or more cells were seen
Time frame: Day 15

Secondary outcomes

Post-surgical Ocular Pain Score: Number of Participants Achieving an Ocular Pain Score of 0
Ocular pain was assessed and graded by the participants using the Visual Analog Scale (VAS). The VAS was scored from 0 to 100 using a mark on the 100 mm line (0=absent \[no pain\], 100=maximum \[severe pain\]).
Time frame: Day 1
Post-surgical Ocular Pain Score: Number of Participants Achieving an Ocular Pain Score of 0
Ocular pain was assessed and graded by the participants using the Visual Analog Scale (VAS). The VAS was scored from 0 to 100 using a mark on the 100 mm line (0=absent \[no pain\], 100=maximum \[severe pain\]).
Time frame: Day 8
Post-surgical Ocular Pain Score: Number of Participants Achieving an Ocular Pain Score of 0
Ocular pain was assessed and graded by the participants using the Visual Analog Scale (VAS). The VAS was scored from 0 to 100 using a mark on the 100 mm line (0=absent \[no pain\], 100=maximum \[severe pain\]).
Time frame: Day 15
Post-surgical Ocular Pain Score: Number of Participants Achieving an Ocular Pain Score of 0
Ocular pain was assessed and graded by the participants using the Visual Analog Scale (VAS). The VAS was scored from 0 to 100 using a mark on the 100 mm line (0=absent \[no pain\], 100=maximum \[severe pain\]).
Time frame: Day 22
Post-surgical Ocular Pain Score: Number of Participants Achieving an Ocular Pain Score of 0
Ocular pain was assessed and graded by the participants using the Visual Analog Scale (VAS). The VAS was scored from 0 to 100 using a mark on the 100 mm line (0=absent \[no pain\], 100=maximum \[severe pain\]).
Time frame: Day 32

Results

Posted Oct 18, 2023

Participant flow

Participant flow — Overall Study
Milestone	SURF-201	Vehicle
Started	40	43
Completed	39	41
Not completed	1	2

Outcome measures

PrimaryAnterior Chamber Cell (ACC) Grade: Number of Participants Achieving an ACC Grade of 0

The Investigator used a slit lamp biomicroscope to assess ACCs in the study (surgery) eye. ACC counts were graded as follows: ACC Grade 0 = 0 cells were seen ACC Grade higher than 0 = 1 or more cells were seen

Time frame:: Day 15
Reported as:: Count of participants · Participants

Anterior Chamber Cell (ACC) Grade: Number of Participants Achieving an ACC Grade of 0
Participants	SURF-201	Vehicle
Anterior Chamber Cell (ACC) Grade: Number of Participants Achieving an ACC Grade of 0	22	9

Statistical analysis

SURF-201 vs Vehicle · z-test for proportions · p = <0.001Other: z-test for proportions, 2-sided test at alpha = 5% level. P-value: based on the normal approximation test for differences between proportions.